Fig. 1.
Evolving decision-making in stage II/III gastric cancer: current practices and future direction. ctDNA, circulating tumor DNA; EBV, Epstein-Barr virus; IM, immune; MSI-H, microsatellite instability–high; XELOX, capecitabine plus oxaliplatin.